Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

RVMD – Revolution Medicines, Inc.

Revolution Medicines, Inc.
RVMD
$36.79
Name : Revolution Medicines, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $6,852,800,000.00
EPSttm : -4.01
finviz dynamic chart for RVMD
Revolution Medicines, Inc.
$36.79
0.33%
$0.12

Float Short %

11.22

Margin Of Safety %

Put/Call OI Ratio

0.78

EPS Next Q Diff

-0.06

EPS Last/This Y

-1.14

EPS This/Next Y

-0.36

Price

36.93

Target Price

72.91

Analyst Recom

1.08

Performance Q

-3.12

Relative Volume

13.16

Beta

1.08

Ticker: RVMD




19 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-06-02RVMD40.660.540.1628324
2025-06-03RVMD40.60.490.2430915
2025-06-04RVMD40.40.460.1131877
2025-06-05RVMD40.210.460.5532007
2025-06-06RVMD41.10.460.4032378
2025-06-09RVMD40.570.440.2233209
2025-06-10RVMD41.980.420.9336076
2025-06-11RVMD40.780.422.1736638
2025-06-12RVMD41.10.420.0836809
2025-06-13RVMD40.590.420.7036915
2025-06-16RVMD39.650.420.1737149
2025-06-17RVMD39.140.410.3437715
2025-06-18RVMD39.930.410.3037786
2025-06-20RVMD39.660.410.0137762
2025-06-23RVMD40.050.700.3723595
2025-06-24RVMD40.050.680.0224061
2025-06-25RVMD38.420.790.2822092
2025-06-26RVMD37.510.791.0322247
2025-06-27RVMD36.920.782.2222101
DateSymbolLastP/C OIP/C VolTotal OI
19 items Current Page1 of 1




19 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-06-02RVMD40.67-38.4-241.2-4.65
2025-06-03RVMD40.58-38.4-195.6-4.65
2025-06-04RVMD40.38-38.4-191.5-4.65
2025-06-05RVMD40.20-38.4-192.0-4.65
2025-06-06RVMD41.08-38.4-226.8-4.65
2025-06-09RVMD40.58-38.4-181.4-4.65
2025-06-10RVMD41.99-38.4-244.3-4.65
2025-06-11RVMD40.79-38.4-160.5-4.65
2025-06-12RVMD41.11-38.4-208.3-4.65
2025-06-13RVMD40.62-38.4-182.1-4.65
2025-06-16RVMD39.76-38.4-170.6-4.65
2025-06-17RVMD39.17-38.4-177.6-4.65
2025-06-18RVMD39.93-38.4-225.2-4.65
2025-06-20RVMD39.66-38.4-188.8-4.65
2025-06-23RVMD40.05-38.4-210.5-4.65
2025-06-24RVMD40.03-38.4-197.7-4.65
2025-06-25RVMD38.41-38.4-143.7-4.65
2025-06-26RVMD37.51-40.4-166.0-4.72
2025-06-27RVMD36.93-40.4-177.8-4.72
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
19 items Current Page1 of 1




18 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-06-02RVMD5.43-0.5711.66
2025-06-03RVMD5.43-0.5711.66
2025-06-04RVMD5.43-0.5711.66
2025-06-05RVMD5.43-0.5711.66
2025-06-06RVMD5.43-0.5711.66
2025-06-09RVMD5.43-0.5011.66
2025-06-10RVMD-0.21-0.5011.66
2025-06-11RVMD-0.21-0.5011.34
2025-06-12RVMD-0.21-0.5011.34
2025-06-13RVMD-0.21-0.5011.34
2025-06-16RVMD-0.21-0.2711.34
2025-06-18RVMD-0.30-0.2711.34
2025-06-20RVMD-0.22-0.2711.34
2025-06-23RVMD-0.23-0.5011.34
2025-06-24RVMD-0.23-0.5011.34
2025-06-25RVMD-0.23-0.5011.34
2025-06-26RVMD-0.23-0.5011.22
2025-06-27RVMD-0.23-0.5011.22
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
18 items Current Page1 of 1

Last Quarter Act. EPS

-1.13

Avg. EPS Est. Current Quarter

-1.14

Avg. EPS Est. Next Quarter

-1.19

Insider Transactions

-0.23

Institutional Transactions

-0.5

Beta

1.08

Average Sales Estimate Current Quarter

28

Average Sales Estimate Next Quarter

28

Fair Value

Quality Score

9

Growth Score

18

Sentiment Score

29

Actual DrawDown %

40.8

Max Drawdown 5-Year %

-73.3

Target Price

72.91

P/E

Forward P/E

PEG

P/S

P/B

3.31

P/Free Cash Flow

EPS

-4

Average EPS Est. Cur. Y​

-4.72

EPS Next Y. (Est.)

-5.08

Target Price Estimates Raised

1

Target Price Estimates Lowered

Profit Margin

Relative Volume

13.16

Return on Equity vs Sector %

-57.5

Return on Equity vs Industry %

-39.6

EPS 1 7Days Diff

-0.1

EPS 1 30Days Diff

-0.07

EBIT Estimation

-177.8
Revolution Medicines, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 616
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291), and zoldonrasib G12D (RMC-9805), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C). The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; RMC-5552, a selective inhibitor of mTORC1 signaling in tumors, which is in phase 1 clinical trial; and RMC-5845 that targets SOS1. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
stock quote shares RVMD – Revolution Medicines, Inc. Stock Price stock today
news today RVMD – Revolution Medicines, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch RVMD – Revolution Medicines, Inc. yahoo finance google finance
stock history RVMD – Revolution Medicines, Inc. invest stock market
stock prices RVMD premarket after hours
ticker RVMD fair value insiders trading